A single - center, retrospective observational study comparing the efficacy of empagliflozin and dapagliflozin as add-on therapy in type 2 diabetic patients

Objective: This study aimed to compare the efficacy of dapagliflozin and empagliflozin as add-on therapies for type 2 diabetes mellitus (T2DM) over 6 months in a real-world setting, focusing on key metabolic parameters.Methods: We conducted a single-center, retrospective observational study involving 74 T2DM patients receiving either dapagliflozin (10mg) or empagliflozin (25mg) as add-on therapy. Data from 843 patients’s electronic medical records were collected at the Center for Endocrinology and Diabetes, Da Nang Family Hospital, between May 2021 and June 2023. Baseline data and data from the 3rd and 6th months of treatment were analyzed using SPSS software (version 20.0). Statistical significance was set at p < 0.05.Results: The mean participant age was 58.8 years, with 54.1% females. Mean baseline HbA1c and fasting blood glucose were 8.18% and 9.1 mmol/L, respectively. After 6 months of SGLT2i treatment, both medications significantly improved glycemic control: HbA1c decreased from 8.18% to 7.3% (p < 0.05), and fasting plasma glucose dropped from 9.1 mmol/L to 7.4 mmol/L (p < 0.05). Systolic blood pressure also decreased significantly, from 130.7 mmHg to 126.5 mmHg (p < 0.05). Although a trend towards weight reduction (1.5 kg) was observed, it was not statistically significant (p > 0.05). Notably, empagliflozin led to a significantly greater decrease in fasting plasma glucose compared to dapagliflozin (p < 0.05). No other significant differences in metabolic parameters were observed between the groups at either 3 or 6 months. Conclusion: Both dapagliflozin and empagliflozin demonstrated significant efficacy as add-on therapies forT2DM patients, improving glycemic control, reducing blood pressure, and potentially promoting weight loss. While empagliflozin showed slightly better BMI, body weight and fasting plasma glucose reduction after 3 months, further research is needed to confirm this finding and explore underlying mechanisms.

Authors

Publication Details

Journal
Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế
Published
2024-09-28
DOI
https://doi.org/10.38103/jcmhch.16.8.12
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A single - center, retrospective observational study comparing the efficacy of empagliflozin and dapagliflozin as add-on therapy in type 2 diabetic patients

Le Van CHi
Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế
Diabetes Treatment and Management
article

A single - center, retrospective observational study comparing the efficacy of empagliflozin and dapagliflozin as add-on therapy in type 2 diabetic patients

Le Van CHi
article en

Abstract

Objective: This study aimed to compare the efficacy of dapagliflozin and empagliflozin as add-on therapies for type 2 diabetes mellitus (T2DM) over 6 months in a real-world setting, focusing on key metabolic parameters.Methods: We conducted a single-center, retrospective observational study involving 74 T2DM patients receiving either dapagliflozin (10mg) or empagliflozin (25mg) as add-on therapy. Data from 843 patients’s electronic medical records were collected at the Center for Endocrinology and Diabetes, Da Nang Family Hospital, between May 2021 and June 2023. Baseline data and data from the 3rd and 6th months of treatment were analyzed using SPSS software (version 20.0). Statistical significance was set at p < 0.05.Results: The mean participant age was 58.8 years, with 54.1% females. Mean baseline HbA1c and fasting blood glucose were 8.18% and 9.1 mmol/L, respectively. After 6 months of SGLT2i treatment, both medications significantly improved glycemic control: HbA1c decreased from 8.18% to 7.3% (p < 0.05), and fasting plasma glucose dropped from 9.1 mmol/L to 7.4 mmol/L (p < 0.05). Systolic blood pressure also decreased significantly, from 130.7 mmHg to 126.5 mmHg (p < 0.05). Although a trend towards weight reduction (1.5 kg) was observed, it was not statistically significant (p > 0.05). Notably, empagliflozin led to a significantly greater decrease in fasting plasma glucose compared to dapagliflozin (p < 0.05). No other significant differences in metabolic parameters were observed between the groups at either 3 or 6 months. Conclusion: Both dapagliflozin and empagliflozin demonstrated significant efficacy as add-on therapies forT2DM patients, improving glycemic control, reducing blood pressure, and potentially promoting weight loss. While empagliflozin showed slightly better BMI, body weight and fasting plasma glucose reduction after 3 months, further research is needed to confirm this finding and explore underlying mechanisms.

Tạp chí Y học lâm sàng Bệnh viện Trung Ương HuếVol. 16(8)
Openalex Percentile: Top 74%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A single - center, retrospective observational study comparing the efficacy of empagliflozin and dapagliflozin as add-on therapy in type 2 diabetic patients — Le Van CHi · Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế (2024) | TGRS Research Map | TGRS